Merck & Co., Inc. (MRK)
| Market Cap | 206.59B |
| Revenue (ttm) | 63.62B |
| Net Income (ttm) | 16.41B |
| Shares Out | 2.50B |
| EPS (ttm) | 6.49 |
| PE Ratio | 12.75 |
| Forward PE | 9.03 |
| Dividend | $3.24 (3.92%) |
| Ex-Dividend Date | Sep 15, 2025 |
| Volume | 10,714,833 |
| Open | 80.75 |
| Previous Close | 80.30 |
| Day's Range | 80.20 - 82.84 |
| 52-Week Range | 73.31 - 120.30 |
| Beta | 0.39 |
| Analysts | Buy |
| Price Target | 108.54 (+31.23%) |
| Earnings Date | Jul 29, 2025 |
About MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janu... [Read more]
Financial Performance
In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for MRK stock is "Buy." The 12-month stock price target is $108.54, which is an increase of 31.23% from the latest price.
News
10 Undervalued Dividend Growth Stocks: August 2025
I rank a selection of undervalued dividend growth stocks in Dividend Radar and present the top ten stocks for consideration. I use two valuation screens, one based on my fair value estimate, and anoth...
KEYTRUDA® (pembrolizumab) plus Padcev® (enfortumab vedotin-ejfv) Significantly Improved Event-Free and Overall Survival and Pathologic Complete Response Rate for Certain Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced positive topline results from the Phase 3 KEYNOTE-905 trial (also known as EV-303) ...
August Dogs Of The Dow Unleashed 19 'Safer' Dividend Buys
Verizon is the only Dow stock currently meeting the 'dogcatcher' ideal: annual dividends from $1K invested exceed its share price and are supported by free cash flow. Analyst forecasts suggest top Dow...
Stock Picks From Seeking Alpha's July 2025 New Analysts
In July, Seeking Alpha welcomed 44 new analysts. This article introduces them and showcases some of their top picks. Analysts provided ratings from Strong Sell to Strong Buy, with detailed justificati...
Income Strategy: I'm Buying 2 Elite Mispriced Dividends
In the current tech-heavy market, I explore two compelling value stocks with strong yields and trade at deep discounts to historical valuations. Both have competitive advantages and strong histories o...
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 8.5% (August 2025)
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filter...
Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges
Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...
Top 10 High-Yield Dividend Stocks For August 2025
My watchlist aims to identify high-quality, high-yield stocks trading at attractive valuations, outperforming benchmarks in yield, and offering strong long-term CAGR. The August 2025 Top 10 list remai...
President Trump demands drugmakers slash prices within 60 days
CNBC's Joe Kernen reports on the latest news.
European drugmakers fall after Trump raises stakes over US drug price cuts
Shares of European drugmakers slipped on Friday after U.S. President Donald Trump sent letters to major pharmaceutical firms to cut drug prices in the United States, months after signing a sweeping ex...
Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says
President Donald Trump demanded several pharmaceutical companies cut down their drug prices for American consumers Thursday, issuing a Sept. 29 deadline for the businesses to “end the free ride of Ame...
Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days.
President Donald Trump on Thursday said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days.
Trump pressures 17 pharma CEOs to cut US drug prices
U.S. President Donald Trump sent letters to the chief executives of 17 major pharmaceutical companies, urging immediate action to lower the cost of prescription drugs for Americans, the White House sa...
Trump posts letters to 17 pharmaceutical companies about drug prices
CNBC's Angelica Peebles joins 'The Exchange' to discuss President Trump posting letters to 17 pharmaceutical companies about drug prices.
Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days
President Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days. It comes after Trump in May signed an executive order reviving a cont...
Merck Stock Is Almost A Classical Benjamin Graham Investment
Merck is good value for money. It is a highly profitable company. It fulfills almost all of Benjamin Graham's stock-picking criteria.
Merck & Co., Inc. (MRK) Q2 2025 Earnings Call Transcript
Merck & Co., Inc. (NYSE:MRK) Q2 2025 Earnings Conference Call July 29, 2025 9:00 AM ET Company Participants Caroline A. Litchfield - Executive VP & CFO Dean Y.
'Halftime' Committee Stocks on the Move: UnitedHealth, Merck, Royal Caribbean and Spotify
The Investment Committee debate some of their stocks on the move lower.
Merck will lay off employees and shed some real estate to cut $3 billion in costs
Merck's stock is falling after a rare revenue miss, and the announcement of a $3 billion cost-cutting plan that will include layoffs.
Merck plans $3 billion cost cuts by end of 2027 - narrows full-year outlook
CNBC's Joe Kernen reports on the company's quarterly earnings results.
Merck to Lay Off Workers and Narrows Guidance as Earnings Fall
Merck said it is embarking on a multi-year cost-savings plan, which includes cuts to its workforce and real-estate footprint, as it looks to redirect resources toward new product launches.
Merck to cut jobs and costs as demand for Gardasil in China remains weak
Drugmaker Merck & Co on Tuesday announced job and cost cuts it said will save $3 billion a year as it posted lower second-quarter results due to continuing weak demand for its Gardasil vaccine in Chin...
Merck plans $3 billion cost cuts by end of 2027 narrows full-year outlook
Merck on Tuesday said it will slash $3 billion in costs by the end of 2027 to be fully reinvested to support new product launches and its drug pipeline. The multi-year effort comes as Merck prepares ...
Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2025 Financial Results
RAHWAY, N.J.--(BUSINESS WIRE)--Merck & Co., Inc., Rahway, N.J., USA Announces Second-Quarter 2025 Financial Results.